NVSNovartis PharmaceuticalsFinished
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Prostate Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2023, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 94 (final count)
- Started
- Jan 25, 2022
- Main results expected
- Dec 8, 2023
- Fully finished
- Apr 20, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 (safety run-in part): Dose Limiting Toxicity (DLT) during 1 cycle (6 weeks)
Measured over: Cycle 2 Day 1 (Day 42)
Part 2 (Post-taxane part) and Part 3 (Pre-taxane part): Overall Response Rate (ORR) based on local assessment
Measured over: From date of the first administration of 177Lu-PSMA-617 until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2023-12-08, no fading
Raw record changes
- none yet
Trial ID NCT05114746 · record last updated 2026-05-08 · checked 2026-11-09 15:47 UTC